Description

SITAJAN MET 50/500 TABLET combines two highly effective antidiabetic agents:

• Sitagliptin Phosphate – 50 mg

• Metformin Hydrochloride – 500 mg

This dual-therapy formulation is designed for adults with Type 2 Diabetes Mellitus who require a combination approach to manage high blood glucose levels, especially when monotherapy alone proves insufficient.

Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that enhances the body’s natural ability to regulate blood glucose by increasing insulin release and decreasing glucagon levels in response to meals.
Metformin is a first-line biguanide oral agent that reduces hepatic glucose production and improves insulin sensitivity.

Together, these agents act synergistically to regulate both fasting and postprandial blood sugar levels, improve HbA1c, and reduce the progression of complications related to diabetes.

• Type 2 Diabetes Mellitus

• Patients inadequately controlled on Metformin or Sitagliptin monotherapy

• Second-line therapy when diet, exercise, and monotherapy are insufficient

• Dual mechanism of action for optimal glycemic control

• Improves insulin sensitivity and secretion in a glucose-dependent manner

• Lower risk of hypoglycemia compared to sulfonylureas

• Proven to reduce HbA1c levels effectively

• Helps in long-term management of diabetes-related complications

• Sitagliptin – DPP-4 inhibitor

• Metformin – Biguanide antidiabetic

• Film-coated tablet for easy administration

• Well-tolerated with a low risk of weight gain

• Manufactured in WHO-GMP, ISO-certified facilities

• Full regulatory and quality documentation available

BLUEPILL EXPRESS is a renowned third-party pharmaceutical manufacturer and global exporter of medicines. We supply high-quality, affordable, and regulatory-compliant products across Asia, Africa, CIS, Latin America, Middle East, and Europe.

Our expertise includes:

• Regulatory documentation (COA, MSDS, Stability Data)

• Custom branding and private label manufacturing

• Secure and timely global logistics

• Dedicated support for large-scale pharma buyers and distributors

• To be taken orally with meals to reduce gastrointestinal side effects

• Dose to be determined by the physician based on individual blood glucose levels

• Not suitable for Type 1 diabetes or diabetic ketoacidosis

• Regular monitoring of kidney function is recommended